Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 17/20 | 0.78 |
| ▸ | RARB | P10826 | 17/20 | 0.78 |
| ▸ | RARG | P13631 | 16/20 | 0.78 |
| ▸ | RXRA | P19793 | 1/20 | 0.78 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561847 | 1.00 | RARA (0.78) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6754150 | 1.00 | RARA (0.78) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807072 | 0.91 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807064 | 0.91 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238262 | 0.88 | RARB (0.83) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238257 | 0.88 | RARB (0.83) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755033 | 0.88 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755036 | 0.88 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL29613352 | 0.88 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7628672 | 0.87 | RARA (0.81) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713515-B2 | ADMINISTERING BENZYL, NAPHTHYL ACID DERIVATIVES | BRISTOL MYERS SQUIBB COMPANY | 2004-03-30 | — | — | US | claimed |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250376462-A1 | ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4647080-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12385013-B2 | Differentiation of pancreatic endocrine cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-31 | — | — | US | disclosed |
| US-12371665-B2 | Differentiation of pancreatic endocrine cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3008168-A2 | SC- CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | President and Fellows of Harvard College (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150240212-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2015-08-27 | — | — | US | disclosed |
| US-20150218522-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2015-08-06 | — | — | US | disclosed |
| WO-2015002724-A2 | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014201167-A1 | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-18 | — | — | WO | disclosed |
| US-6713515-B2 | ADMINISTERING BENZYL, NAPHTHYL ACID DERIVATIVES | BRISTOL MYERS SQUIBB COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20020120006-A1 | Retinoic acid receptor antagonists as promoters of angiogenesis | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | disclosed |
| WO-2002022113-A2 | RETINOIC ACID RECEPTOR ANTAGONISTS AS PROMOTERS OF ANGIOGENESIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6319948-B2 | PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120006-A1 | Retinoic acid receptor antagonists as promoters of angiogenesis | RARB, RARG, RARA | RARA 3/4885RARB 1/4885RARG 2/4885 |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
| US-20250376462-A1 | ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USE | IAPP, PNLIP, CEL | RARA 3638/4885RARB 2557/4885RARG 2394/4885 |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, CTNND1, CTNNBL1 | RARA 3678/4885RARB 3103/4885RARG 3332/4885 |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | IAPP, CBX6, HLA-C | RARA 1440/4885RARB 1354/4885RARG 584/4885 |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | CD47, IAPP, B2M | RARA 4032/4885RARB 3272/4885RARG 3818/4885 |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, GPR119 | RARA 156/4885RARB 38/4885RARG 57/4885 |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, CTNND1 | RARA 3302/4885RARB 2814/4885RARG 3136/4885 |
| US-12385013-B2 | Differentiation of pancreatic endocrine cells | IAPP, PNLIP, GPR119 | RARA 145/4885RARB 50/4885RARG 64/4885 |
| US-12371665-B2 | Differentiation of pancreatic endocrine cells | IAPP, PNLIP, GPR119 | RARA 145/4885RARB 50/4885RARG 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.